Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma – guidance (TA658)

Isatuximab, plus pomalidomide & dexamethasone, is recommended within the Cancer Drugs Fund for relapsed/refractory multiple myeloma in adults, only if they have had 3 previous lines of treatment including lenalidomide & a proteasome inhibitor.

National Institute for Health and Care Excellence